Once regarded as passive additives, excipients have taken on a far more strategic role in pharmaceutical development. No longer just fillers or binders, these materials now directly influence key formulation attributes, such as bioavailability, mechanical integrity, processability and shelf stability. With regulatory expectations growing more exacting and formulation windows tightening, the ability to predict and optimize excipient behavior within complex drug systems has become a defining capability for forward-thinking developers. That’s where Boai NKY Pharmaceuticals leads the market today. Rooted in advanced materials science, NKY designs excipients that not only meet monograph specifications but anticipate the functional realities of modern drug delivery. Every grade is developed with formulation behavior in mind, ensuring consistency across batches, platforms and regulatory environments. Whether addressing solubility challenges, scale-up risks or long-term stability, NKY’s excipients are built to perform where it matters most: inside the finished dose. “Knowing the chemistry is foundational, but it’s only part of the equation,” says Dr. Herb Ulmer, chief scientist. “Our work begins where the datasheet ends. We’re focused on how the excipient performs across the lifecycle, from bench to batch to shelf.” Specializing in polyvinylpyrrolidone (PVP) and PVM/ MA copolymers, NKY serves formulators working across pharmaceuticals, personal care, and food industries. Each excipient is developed considering how it would behave under compression, respond in high-shear environments, interact over time with other actives and withstand real-world storage and transport conditions. Engineering excipients with functional resilience in mind means fewer surprises during tech transfer, reduced formulation drift over time and more consistent performance across global manufacturing sites. Where Formulation Challenges Meet Functional Chemistry While most PVP suppliers focus on meeting purity benchmarks and regulatory checklists, NKY takes the next step, helping clients shift from trial-and-error to performance-driven product development..

Seoul Clinical Laboratories (SCL) has been advancing in clinical diagnostics for over four decades and more recently through AI-driven prediction test service and digital pathology systems. These technologies are transforming how healthcare professionals detect and diagnose diseases, improving accuracy and speed. By enhancing workflows and providing deeper insights, SCL empowers clinicians to make faster, more confident decisions. Through its focus on advanced technologies, SCL ensures that medical professionals are equipped with the tools to provide better patient care. SCL’s commitment to technological progress is exemplified by its AI-based prediction test service, the first of its kind among reference laboratories in South Korea. It leverages AI to estimate the risk of urinary tract infections based on urinalysis results. By providing healthcare professionals with predictive data, SCL enables quick, accurate diagnoses, ultimately reducing the time patients spend waiting for treatment. The integration of AI into diagnostic processes marks a significant leap forward, and SCL is actively developing further applications of AI, including rapid diagnostic tools powered by large language models and computer vision. These innovations are paving the way for a new era of clinical diagnostics that is faster, more accurate and more accessible. “At SCL, we believe in pushing the boundaries of technology to empower clinicians with the tools they need to diagnose confidently and precisely,” says Kyoung-Ryul Lee, MD, PhD. Another significant milestone of SCL is its collaboration with Philips to establish the first digital pathology system among reference laboratories in South Korea. This enhances diagnostic accuracy by structuring and standardizing pathologic diagnoses. By digitizing pathology workflows, it reduces the workload and streamlines the storage and retrieval of slides, improving access to past data and enabling more effective clinical decision-making. SCL’s digital pathology system lays the foundation for further transformative developments in AI-powered pathology and big data research in medical diagnostics. Commitment to Quality Beyond technological innovation, SCL stands out for its unwavering commitment to quality and regulatory compliance. The company made history in South Korea by receiving accreditation from the College of American Pathologists, a distinction that underscores its dedication to maintaining the highest standards in clinical testing. In 2021, SCL also achieved ISO 15189 accreditation, affirming its adherence to internationally recognized standards for medical laboratories. These are just the beginning of SCL’s pursuit of excellence. In 2023, the company became the first clinical testing institution in Asia to receive the A2LA ISO 20387 certification for biobanks. This prestigious certification enhances SCL’s capabilities in supporting scientific and clinical research with high-quality biospecimens, ensuring that its storage processes meet global standards for accuracy and reliability..

Bringing medical devices and drugs from R&D labs to patients demands precision at every step. Accuracy in language is crucial to guarantee that scientific data, regulatory submissions and clinical documentation are correctly conveyed. A single misstep can lead to costly delays, regulatory setbacks and safety risks. Regulus Pharma Services is a trusted partner for pharmaceutical companies, biotech innovators and medical device manufacturers seeking precise, reliable translation services for global regulatory processes. From investigational drug brochures, clinical trial protocols and standard technical documents to package inserts, inquiries and biotechnology documents, Regulus Pharma ensures that complex science is translated into clear, compliant communication. In an industry where every word can make or break a breakthrough, Regulus Pharma is the silent force helping innovation reach the world. “Our mission has always been to provide consistent, best-quality translation services to help our clients seamlessly navigate the development and regulatory processes,” says Katsuo Hoshi, representative director. Regulus Pharma began as a general technical translation agency, assisting industries with translating export manuals and consumer product documentation. Later, a pivotal partnership with a bilingual Japanese-American physician shifted the organization’s focus to the medical, pharmaceutical and biotechnology sectors. Over the years, Regulus Pharma has evolved alongside industry demands. Today, it focuses on regulatory science, providing translation services at every stage of drug and medical device development. These include preclinical studies, clinical trials, new drug applications, consultations with regulatory authorities and post-approval activities, and post-marketing surveillance. Minimizing Errors, Maximizing Consistency A key element of Regulus Pharma’s strength is its carefully curated network of expert translators. Each translator brings extensive experience in medical and pharmaceutical translation, and many hold advanced academic degrees, including Ph.Ds in medical science..